H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Axsome Therapeutics to $180 from $190 and keeps a Buy rating on the shares post the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXSM:
- Piper upgrades Axsome to Overweight on commercial expansion
- Axsome Therapeutics upgraded to Overweight from Neutral at Piper Sandler
- Cantor Fitzgerald bullish on Axsome after Q2 results, Sage’s zuranolone CRL
- Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- Axsome Therapeutics announces anticipated milestones